AMGN Sep 2024 180.000 put
| Previous close | 1.1000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.8400 |
| Strike | 180.00 |
| Expiry date | 2024-09-20 |
| Day's range | 1.1000 - 1.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
- Yahoo Finance Video
Weight-loss drug competition heats up. Is Wegovy in trouble?
The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
- Yahoo Finance Video
Amgen, DraftKings, Live Nation: Trending tickers
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
Insider MonkeyAmgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript May 2, 2024 Amgen Inc. beats earnings expectations. Reported EPS is $3.96, expectations were $3.88. Amgen Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: My name is Julianne, and I will […]
